Health Trials

Telitacicept

4

Review clinical trials related to Telitacicept. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients

Participants needed: 30
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: Zhejiang Provincial People's HospitalUpdated: Mar 30, 2026Locations: 1
Eligibility criteria

1. Age 18-85 years [+3]

1. Exclusion of patients with severe diseases of major organs (e.g., heart, live... [+7]

Read more
Status: Recruiting

Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis

The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patients

Participants needed: 20
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: Zhejiang Provincial People's HospitalUpdated: May 18, 2025Locations: 1
Eligibility criteria

Age 18-85 years [+3]

Exclusion of patients with severe diseases of major organs (e.g., heart, liver,... [+6]

Read more
Status: Recruiting

Efficacy and Safety of Telitacicept in IgAN

A study to evaluate efficacy and safety of telitacicept in the treatment of patients with primary IgA nephropathy at high risk of progression.

Participants needed: 118
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Jan 1, 2025Locations: 1
Eligibility criteria

18-70 years old, male or female [+6]

Patients with abnormal laboratory indicators (see study protocol for details). [+13]

Read more
Status: Recruiting

Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome

The main objective is to evaluate the effectiveness of telitacicept in pediatric patients with frequently relapsing or steroid dependent nephrotic syndrome within the 52-week follow-up.

Participants needed: 20
Trial details
Phase: Phase 3Age: 2-18Biological sex: AllType: InterventionalSponsor: The Children's Hospital of Zhejiang University School of MedicineUpdated: Aug 21, 2024Locations: 1
Eligibility criteria

Sensitive but frequent relapses or steroids dependence nephrotic syndrome [+4]

Family history of nephrotic syndrome, chronic glomerulonephritis or uremia [+10]

Read more